Staphylococcus epidermidis Bacteria Reduction

Authors
Jessica Dobbin, BSc BA
Facility
Novaerus Research and Development Labs; Ireland
Download
Full Report

Objective

To evaluate the efficacy of the Defend 1050 on reducing airborne Staphylococcus epidermidis bacteria, a surrogate for methicillin-resistant Staphylococcus aureus (MRSA). MRSA is an example of a superbug.

Methodology

The test environment was a 30 m3 test chamber, located in the Novaerus microbiology laboratory. During the testing, the Defend 1050 device was placed inside the chamber at the centre, with the air inlet facing towards the door of the chamber. The Defend 1050 device was tested at maximum airflow, speed setting 5. The test chamber was controlled for temperature and humidity at 77ºF and 50% relative humidity.

Results

The Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis, a surrogate for methicillin-resistant Staphylococcus aureus (MRSA), within 15 minutes of operation.

Staph_Epidermidis_1050_Graph_WA.png

Contact

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118
info@wellairsolutions.com

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750
info@wellairsolutions.com

Contact WellAir

Social

Partners